http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1331567-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3417b0003a1d876c4f9d2b5e1ee565c8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 1989-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1994-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a04bec1e9ffc2f652457067d65ad655a |
| publicationDate | 1994-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1331567-C |
| titleOfInvention | Use of heterocyclic compounds for iontophoretic treatment or for the production of pharmaceuticals for iontophoretic treatment of malignant tumors as well as lubricants or partingcompounds, anesthetics and prophylactics to be used during this treatment |
| abstract | ABSTRACT What is disclosed is the use of dissociable heterocycic compounds from the group including aminoacridine, aminocholine and aminopyridine as well as their derivatives substituted on the basic striucture, which are present in tautomeric diimine form, for the selective iontophoretic treatment or for production of a pharmaceutical for iontophoretic treatment and relapse prophylaxis of bladder cancer as well as for iontophoretic treatment of malignant skin and mucus membrane tumors. It is further disclosed and proven that the antineoplastic effect observed with use of the above compositions in animal experiments and in clinical treatment is selective and healthy tissue is not damaged. The common denominator for the characteristic and proven antineoplastic selectivc effect of the three classes of materials is the tautomeric diimine form. As a pre- and/or post-treatment medium with the treatment of bladder cancer, preferably a lubricant, anesthetic and prophylactic medium is used, which includes a) a nonionic, water miscible lubricant with an electrlc conductivity lower than 2 mS/cm and a viscosity (at 25 ° C) in the range of 50 to 2000 mPa.s, and b) a local, nonionic mucus membrane anesthetic which does not penetrate into the bloodstream, in which the mixture of (a) and (b) has a pH level between approxiamtely 5 and 7.5, preferably between 6.5 and 6.8. |
| priorityDate | 1988-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.